Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.
Also called NCT03353350
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 406 participants
- Registry
-
NCT03353350
-
- Other papers using this trial's data
- Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Poland, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03353350. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-05 (actual); primary completion 2020-01-29 (actual). Results posted on 2022-01-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
- Acronym
- AMPLITUDE-M
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- efpeglenatide (SAR439977)
- Intervention (Drug)
- placebo
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03353350- Content hash
34fde62ce63d1c78d8d30453a742969b20cce8036ff590412a65c58d4ee3ed2a